Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...
Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Jamie Thomas discussing results from the MAST trial assessing the validation of PAM50 for predicting progression in ...
Elevai Labs (NASDAQ:ELAB – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap multi-sector conglomerates companies, but which is the superior business? We will compare the ...
Jacob E. Berchuck, MD, highlights challenges in adopting liquid biopsy for PSMA expression and its potential to revolutionize precision medicine in prostate cancer.
MedPage Today on MSN20h
Paradoxical PSA Association With Mortality After Radical ProstatectomyIn the study cohort, 2,310 patients died during a median follow-up of 6.3 years, and prostate cancer accounted for 454 (19.7% ...
ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback